Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia

NCT01217944 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

277

Enrollment

INDUSTRY

Sponsor class

Conditions

Pathological Myopia

Interventions

DRUG: Ranibizumab
DRUG: Verteporfin PDT
DRUG: Sham Ranibizumab
DRUG: Sham verteporfin PDT

Sponsor

Novartis Pharmaceuticals